Better days and better nights start with Omnipod® 5
More time for life. More time in range.
Omnipod® 5 continuously receives glucose readings from a compatible CGM and automatically increases, decreases or pauses insulin delivery based on predicted glucose levels.
The result is a system designed to help keep glucose levels in range1,2 while reducing the day-to-day effort of diabetes management.
Omnipod 5 is compatible with Dexcom G7 CGM System, FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus sensors.
Why people switch to Omnipod® 5
From multiple daily injections (MDI)
- Spend an average of 5.4 more hours per day in range, with no increase in time below range3
- Replace multiple daily injections with one Pod for up to 3 days (72 hours)
- Automated insulin adjustments every 5 minutes
From a traditional tubed insulin pump
- Small Pod worn directly on the body
- Completely tubeless, with no tubing to disconnect or catch
- 91% of users said they would not go back to a tubed pump4
More than just a tubeless insulin pump
Omnipod 5 automatically adjusts insulin delivery to help keep glucose levels steadier, day and night. Approved for people with T1D ages 2-and-up.
Less calculating at mealtimes
Save frequently eaten foods, meals, or snacks with preset carb amounts, then let the SmartBolus Calculator do the math for you. Perfect for:
- repeat meals
- kids' lunches
- favourite snacks
- busy schedules.
Designed to keep up with life
When enabled, the Activity feature reduces insulin delivery when glucose has the potential to go low. Ideal for:
- Exercise
- Sleepovers
- Sick days
- Any time you want reduced insulin delivery
Omnipod is available on the NDSS
Omnipod® 5 is partially subsidised through the NDSS for eligible people with type 1 diabetes, helping to reduce the ongoing cost of Omnipod 5 Pods.
Hear real Podder stories
You can almost forget about having type one wearing this pump... it's given me the first idea of what it's like to live with a working pancreas.
Richard
Podder® since 2024
Omnipod 5 has allowed us to give Priya the freedom that all kids deserve, whilst not compromising her safety or worrying about disconnecting her from her insulin delivery.
Kimmie – Mother of Priya
Podder® since 2023
Omnipod 5 reduces the burden of diabetes, it increases your quality of life and I couldn’t have even imagined something like this when I was first diagnosed.
Lydia P.
Podder® since 2014
Try it before committing
Order a free Pod Experience Kit* to get a feel for Omnipod in your daily routine. No needles, no commitment.
If you have Type 2 Diabetes please speak with your healthcare professional before you request a call as you might not be considered suitable to use Omnipod®
2. Sherr JL, et al. Diabetes Care (2022). Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 39.4% vs. 29.5%. Average time with low blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 3.43% vs. 2.46%. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%.
3. Wilmot E, et al. Lancet (2026); A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) [51% HbA1c≥ 8% (64 mmol/mol)] with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Time in range (70-180 mg/dL or 3.9-10mmol/L) with OP5 improved by 22% (43% MDI vs. 65% OP5, p<0.001). Time below range (<70 mg/dL or <3.9mmol/L) with OP5 was non-inferior to MDI (2.27% MDI vs. 2.56%, p=0.2).
4. 2025 Customer Survey of U.S. adults with Type 1 diabetes using Omnipod 5, (n=1,230), 91% agreed would not go back to tubes. Data on file. RF-082025-00063.
5. Wilmot E, et al. Lancet (2026); A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) [51% HbA1c≥ 8% (64 mmol/mol)] with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Time in range (70-180 mg/dL or 3.9-10mmol/L) with OP5 improved by 22% (43% MDI vs. 65% OP5, p<0.001). Time below range (<70 mg/dL or <3.9mmol/L) with OP5 was non-inferior to MDI (2.27% MDI vs. 2.56%, p=0.2). Study funded by Insulet.
6. Insulet Data on File. 2024. A 13-week randomised controlled trial conducted among 194 adults (age 18-70 years) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery (AID) System versus conventional non-AID pump therapy and CGM (control). At 13-weeks of Omnipod 5 use 130 participants were asked via a System Usability Survey (SUS) if the system was easy to use. 71.5% of participants strongly agreed and 19.2% agreed. RF-112024-00029. Study funded by Insulet
7. 2025 Customer Survey of U.S. adults with Type 1 diabetes (n=1230), 92% agreed Omnipod 5 gives them peace of mind. Survey funded by Insulet.